Oxford University said the first volunteer has received an experimental vaccine tailored to the Bundibugyo Ebola strain, which has no approved vaccine or specific treatment.
3,200 confirmed infections and 1,405 deaths have been recorded in the Democratic Republic of Congo since late April, with authorities saying improved detection and expanded testing partly explain the sharp rise.
Almost 90% of cases are in Ituri province near the Uganda and South Sudan borders, but the outbreak has already spread to five provinces in the conflict-scarred east.
Strikes by health workers over unpaid wages have hampered the response in some hospitals, and experts warn the epidemic could continue for several more months.
As experimental vaccines are rushed to the frontlines, will they arrive in time to stop the outbreak from breaching more international borders?
Since better testing partly explains the recent surge, is the true scale of the Congo outbreak already far worse than official numbers suggest?
With health workers striking and the virus spreading, could this rare Ebola strain truly rival the devastating 2014 West Africa epidemic?
2026 Bundibugyo Ebola Outbreak: Explosive Spread, Vaccine Gaps, and the Challenge of Conflict Zones
Overview
The 2026 Bundibugyo Ebola outbreak in the DRC and Uganda escalated rapidly after initial cases were confirmed and the WHO declared a global emergency. Early detection was hampered because Bundibugyo Ebola often causes vague symptoms, leading to delayed clinical recognition and silent community spread. Existing Ebola vaccines do not protect against this strain, as they target the Zaire variant, and past outbreaks were too small to drive vaccine development. As a result, the world raced to develop new vaccines like Oxford’s ChAdOx1 BDBV, designed for easy storage and use in remote areas. Meanwhile, deep community distrust, fueled by rumors and cultural tensions, led to violence, disrupted care, and allowed the virus to spread further, highlighting the urgent need for both medical and social solutions.